NanoVibronix Featured in Your Bladder Health Magazine
- UroShield's feature in a health magazine can raise market and clinician awareness, potentially increasing sales and adoption.
- Testimonials provide compelling evidence of the positive impact on patients' quality of life.
- None.
UroShield Cited as Effective in Preventing CAUTIs and Blockages and Having a Major Impact on Quality of Life
(Graphic: Business Wire)
Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., said, “This article reinforces our efforts to raise market and clinician awareness, a key driver to accelerating adoption and increasing sales. It highlights the effectiveness of UroShield in preventing episodes of CAUTI and blockages, which in turn, reduces the need for antibiotics and prolonged hospital stays, thereby lowering healthcare costs. Just as important, the patient testimonials and endorsements provide compelling evidence of the positive impact UroShield can have on a patient’s quality of life.”
From the article:
‘Currently, even after many years, the most effective treatments are frequent catheter changes for catheter blockages, and possibly antibiotics for CAUTIs and in more serious cases hospital inpatient episodes, with IV antibiotics to resolve.
Not only does this all have a major impact on people’s quality of life, and the already mentioned strain on NHS resources and finances, but the increased use of antibiotics is something which is of concern globally.
Thankfully UroShield addresses and solves all these serious concerns and has some additional benefits to users in reducing pain associated with catheter use, and a reduction in bladder spasms which some people suffer from.’
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale of our products; (iv) intense competition in the medical device industry from much larger, multinational companies; (v) product liability claims; (vi) product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and/or other third party payers for our products; (ix) our ability to successfully obtain and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare system in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206453100/en/
Investor Contact:
Brett Maas, Managing Principal, Hayden IR, LLC
brett@haydenir.com
(646) 536-7331
Source: NanoVibronix, Inc.
FAQ
What is the company behind UroShield?
What is the effectiveness of UroShield?
What are the additional benefits of UroShield?
Where can I find the full release?
